Navigating the Genomic Labyrinth: The Complexities, Clinical Trials, and Future Frontiers of HRD Testing in Ovarian Cancer

Executive Overview

Testing for homologous recombination deficiency (HRD) has emerged as a cornerstone of personalized oncology, particularly in the management of high-grade serous ovarian carcinomas. However, as clinical applications expand, pathologists and oncologists find themselves navigating a highly complex diagnostic landscape. Far from a simple binary determination, HRD testing requires a sophisticated understanding of germline alterations, somatic mutations, epigenetic silencing, and the structural "genomic scars" left by defective DNA repair mechanisms.

The clinical stakes are remarkably high. Accurately identifying HRD status determines whether a patient will benefit from Poly (ADP-ribose) polymerase (PARP) inhibitors—such as olaparib, niraparib, and rucaparib—which have fundamentally transformed the survival outlook for ovarian cancer. Yet, the path to a definitive diagnosis is fraught with pre-analytical, analytical, and clinical hurdles. Different clinical trials have utilized varying genomic instability score (GIS) cutoffs, and patient cohorts have featured diverse inclusion criteria.

Furthermore, the emerging biology of homologous recombination proficient (HRP) tumors is beginning to challenge the established binary paradigm, forcing a critical re-evaluation of how molecular pathology laboratories approach ovarian cancer diagnostics.

Detailed Chronology: The Evolution of HRD Clinical Trials

The current framework for HRD testing and PARP inhibitor (PARPi) utilization was built on a series of landmark clinical trials, each introducing unique patient cohorts, therapeutic regimens, and genomic cutoffs. Understanding this timeline is essential for clinical decision-making.

[2018] SOLO1 Trial
  │  └─ Focus: Newly diagnosed high-grade serous/endometrioid ovarian cancer
  │  └─ Biomarker: Germline/somatic BRCA1/2 mutations
  │  └─ Outcome: Maintenance Olaparib reduced risk of progression/death by 70%
  │
[2019] PRIMA Trial
  │  └─ Focus: Newly diagnosed high-grade ovarian cancer
  │  └─ Biomarker: HRD defined as BRCA mutant OR GIS ≥ 42 (Myriad MyChoice)
  │  └─ Outcome: Significant Niraparib benefit in HRD; modest benefit in HRP
  │
[2019] PAOLA-1 Trial
  │  └─ Focus: First-line maintenance regardless of BRCA status
  │  └─ Biomarker: HRD defined as GIS ≥ 42
  │  └─ Regimen: Olaparib combined with Bevacizumab
  │
[2019] VELIA Trial
     └─ Focus: Aligned chemotherapy and maintenance regimens
     └─ Biomarker: Established a lower HRD cutoff of GIS ≥ 33

2018: The SOLO1 Trial

The therapeutic paradigm shifted dramatically with the publication of the SOLO1 trial (N Engl J Med. 2018;379[26]:2495–2505). This study evaluated maintenance olaparib in 391 patients with newly diagnosed, advanced (Stage III–IV) high-grade serous or endometrioid ovarian cancer. Crucially, the cohort was restricted to patients harboring BRCA1 or BRCA2 mutations (388 germline, 2 somatic).

The results were unprecedented: after a median follow-up of 41 months, maintenance olaparib achieved a 70% reduction in the risk of disease progression or death compared to placebo. SOLO1 established BRCA1/2 mutational status as a mandatory biomarker in ovarian cancer but left open the question of how to identify and treat patients who lacked these specific mutations but possessed similar DNA repair defects.

2019: The PRIMA, PAOLA-1, and VELIA Trials

The year 2019 brought a wave of clinical data that expanded the scope of PARP inhibition beyond BRCA mutations to the broader concept of HRD:

• The PRIMA Trial (N Engl J Med. 2019;381[25]:2391–2402) investigated the PARP inhibitor niraparib as first-line maintenance therapy. It categorized patients based on their HRD status, defined as either the presence of a deleterious BRCA mutation or a Genomic Instability Score (GIS) of 42 or higher (using the Myriad MyChoice assay). Of the 733 patients enrolled, 373 had HRD-positive tumors (223 with BRCA mutations, 150 without). Niraparib demonstrated significant progression-free survival (PFS) benefits in the HRD cohort, but also showed a modest benefit in the HR-proficient cohort, hinting at alternative mechanisms of action or limits in current testing sensitivity.
• The PAOLA-1 Trial (N Engl J Med. 2019;381[25]:2416–2428) evaluated the combination of olaparib and the anti-angiogenic agent bevacizumab as first-line maintenance. This trial also utilized a GIS cutoff of 42 to define HRD. The combination therapy showed substantial PFS improvements, particularly in patients whose tumors were HRD-positive, irrespective of whether they carried a BRCA mutation.
• The VELIA Trial (N Engl J Med. 2019;381[25]:2403–2415) evaluated veliparib added to front-line chemotherapy and continued as maintenance. Distinctly, VELIA utilized a different threshold for genomic instability, setting the HRD positivity cutoff at a GIS of 33 or higher.

This variation in cutoffs (42 in PRIMA/PAOLA-1 vs. 33 in VELIA) introduced a persistent clinical challenge: a subset of patients falling into the "gray zone" (scores between 33 and 41) would be classified as HRD-positive under one trial protocol but HRD-negative under another.

Supporting Context & Metrics: The Biology and Diagnostics of HRD

The Molecular Mechanism of Homologous Recombination

To appreciate the diagnostic challenges, one must understand the underlying molecular biology. DNA double-strand breaks (DSBs) are highly lethal forms of cellular damage. In healthy somatic cells, homologous recombination (HR) serves as a high-fidelity, error-free repair mechanism that uses a sister chromatid as a template to perfectly restore the genomic sequence.

When the HR pathway is compromised—either through germline or somatic mutations in BRCA1, BRCA2, or auxiliary genes like PALB2, RAD51C, RAD51D, BRIP1, ATM, and CHEK2, or via epigenetic silencing (methylation) of BRCA1/2—the cell is forced to rely on alternative, highly error-prone pathways, such as Non-Homologous End Joining (NHEJ) or Microhomology-Mediated End Joining (MMEJ). These backup pathways introduce significant structural errors during repair.

       [ Double-Strand DNA Break ]
                    │
         Is the HR Pathway Intact?
          /                       
       YES                         NO (HRD)
        │                             │
 [High-Fidelity Repair]      [Error-Prone Pathways]
  (Sister Chromatid Template) (NHEJ / MMEJ backup)
        │                             │
 [Genomic Integrity]         [Genomic Scars Accumulate]
                              ├─ Loss of Heterozygosity (LOH)
                              ├─ Telomeric Allelic Imbalance (TAI)
                              └─ Large-scale State Transitions (LST)

Measuring the "Genomic Scar"

The biological consequence of relying on error-prone repair pathways is the accumulation of permanent structural damage across the genome. These permanent chromosomal alterations are referred to as "genomic scars." Currently, clinical assays measure these scars through three distinct parameters to calculate a Genomic Instability Score (GIS):

1. Loss of Heterozygosity (LOH): The permanent loss of one of the two parental alleles across chromosomal regions.
2. Telomeric Allelic Imbalance (TAI): Unequal allelic representation extending to the telomeric ends of the chromosomes.
3. Large-scale State Transitions (LST): Chromosomal breaks and rearrangements of at least 10 megabases in size, indicative of severe genomic structural disintegration.

The cumulative presence of these three markers provides a surrogate measure of a tumor’s historic failure to execute homologous recombination. Importantly, these scars themselves do not drive cancer or therapeutic sensitivity; rather, they serve as historical molecular evidence of a repair defect. It is the active, ongoing repair defect that renders the tumor highly vulnerable to platinum-based chemotherapies and PARP inhibitors, which exploit synthetic lethality.

Pre-Analytical Hurdles and Tumor Heterogeneity

The clinical utility of HRD testing is frequently limited by pre-analytical specimen constraints. Detecting copy number alterations and genomic scars requires a significantly higher tumor cell content than standard single nucleotide variant (SNV) detection.

Furthermore, high-grade serous ovarian cancer is notoriously heterogeneous. Studies have demonstrated that testing different regions of the same tumor can yield discordant GIS results, particularly for patients whose scores hover near the established cutoff of 42. A single patient’s tumor could test as HR-deficient (score of 43) in one region and HR-proficient (score of 40) in another, creating a difficult clinical dilemma for oncologists.

The Testing Market: Approved Assays vs. Laboratory-Developed Tests

Pathologists are currently tasked with choosing between FDA-approved companion diagnostics and comprehensive laboratory-developed tests (LDTs):

• Myriad MyChoice CDx: This assay is widely considered the clinical standard because it was utilized in the pivotal PRIMA and PAOLA-1 trials. It evaluates BRCA1/2 mutational status and calculates a GIS based on LOH, TAI, and LST, using a validated cutoff of 42.
• FoundationOne CDx: Another FDA-approved platform, this comprehensive genomic profiling (CGP) assay assesses BRCA1/2 status and reports genomic loss of heterozygosity (gLOH) as a surrogate for HRD.
• Labcorp OmniSeq Insight: Representing the next generation of advanced molecular profiling, this laboratory-developed test (LDT) utilizes an optimized version of Illumina’s TSO 500 HRD workflow. It sequences the coding regions of 523 genes on the DNA side to detect SNVs, indels, and copy number variations, alongside 55 RNA genes for fusions, microsatellite instability (MSI), tumor mutational burden (TMB), and PD-L1 immunohistochemistry. This panel-based approach provides a broader biological context than standalone HRD assays.

Official Statements and Professional Guidelines

The integration of HRD testing into routine clinical care is strongly supported by major oncology and pathology organizations.

Medical Society Recommendations

• The National Comprehensive Cancer Network (NCCN): Recommends that all patients diagnosed with ovarian, fallopian tube, or primary peritoneal cancer undergo genetic risk evaluation, including both germline and somatic biomarker testing.
• The American Society of Clinical Oncology (ASCO): Endorses universal germline testing for BRCA1/2 and other susceptibility genes. For women who test negative in the germline, somatic tumor testing for BRCA1/2 pathogenic or likely pathogenic variants must be performed.
• The Society of Gynecologic Oncology (SGO) & The American College of Obstetricians and Gynecologists (ACOG): Support universal germline and somatic testing for all epithelial ovarian cancer patients, emphasizing the role of cascade testing for at-risk family members.

Expert Perspectives

Reflecting on her early experiences with the technology, Dr. Tricia Numan, MD, gynecologic pathologist and director of the Women’s Health Initiative at Roswell Park Comprehensive Cancer Center, noted:

"When I first became involved in the topic, I didn’t realize how many components went into HRD testing, including germline alterations, somatic alterations, and various classifications of genomic instability. Moreover, the key clinical trials to date have used different cutoff numbers for their genomic instability score… I don’t think everyone appreciates that. It’s very complex."

Regarding the clinical "gray zone" and tumor heterogeneity, Dr. Numan added:

"For better or for worse, our clinical colleagues may see the HR result as very black and white. But as recent studies looking at tumor heterogeneity have shown, there can be cases where one tumor can be tested multiple times with different results, especially those that test around the 42 cutoff. Three times it may be considered deficient, and the fourth time it’s considered proficient. If the score results at 41, it might be worth it to test another area of the tumor and to also consider the genetic alterations associated with the tumor."

Dr. Kyle Strickland, MD, PhD, director of medical affairs at Labcorp, emphasized the biological significance of HRD:

"Whether the alteration is germline or somatic, the biological consequence can be the same: impaired homologous recombination repair at the tumor level. HRD is a driver of cancer. We know this because patients with pathogenic BRCA1 and BRCA2 mutations in the germline are at an increased risk for cancer."

Addressing the critical requirement for high-quality tissue specimens, Dr. Strickland remarked:

"We can do a lot with a little, but we can’t do everything with a little. The tumor content that we need to call copy number loss accurately is actually really high—50 percent tumor content on the slide. I don’t think our patient providers truly recognize that sending in large pieces of tumor, that are untreated, is probably the best way to get a good result."

Future Outlook: Emerging Paradigms and Next-Generation Biomarkers

The clinical understanding of HRD and ovarian cancer biology is evolving rapidly. Future advances are expected to expand therapeutic options for patients who do not fit the classic HRD profile.

                  [ Ovarian Cancer Profiling ]
                   /                        
        [ HR-Deficient (HRD) ]       [ HR-Proficient (HRP) ]
          │                            │
          ├─ BRCA1/2 mutations         ├─ CCNE1 Amplification (Replication Stress)
          ├─ Non-BRCA HRR mutations    └─ RB1 Status Check
          └─ High GIS (≥42)                  ├─ RB1 Lost: "HRD-like" behavior
                                             └─ RB1 Retained: Aggressive phenotype

Deciphering the Homologous Recombination Proficient (HRP) Tumor

Historically, HRP tumors have been defined by what they lack: they show no evidence of HR defects, have low genomic instability scores, and are largely resistant to PARP inhibitors. However, researchers are actively seeking to identify alternative therapeutic vulnerabilities within this population.

A key area of investigation centers on replication fork stress. HRP tumors frequently exhibit high expression of CCNE1 (cyclin E1). High-level amplification of CCNE1 is essentially mutually exclusive with the HRD phenotype. In clinical practice, identifying a robust CCNE1 amplification in a tumor with a borderline GIS suggests the tumor is truly HR-proficient, helping clinicians avoid ineffective PARP inhibitor therapies.

The Role of RB1 Loss in HRP Tumors

Emerging data suggest that HRP tumors are not a uniform group. In a study published in Scientific Reports (Sci Rep. 2025;15[1]:29523), Dr. Strickland and his colleagues identified a subset of HRP tumors characterized by the loss of the cell cycle regulator RB1.

Interestingly, HRP tumors with RB1 loss behave more like HRD tumors, demonstrating increased proliferation and a potential survival advantage when treated with specific chemotherapies. Conversely, HRP tumors that retain RB1 represent an aggressive phenotype with significantly shorter overall survival, highlighting an urgent need for novel therapeutic targets.

Epigenetic Regulation and BRCA Methylation

A major challenge in current HRD diagnostics is the inability to track epigenetic dynamics. Somatic loss of BRCA function frequently occurs through promoter methylation rather than gene mutation. Because methylation is reversible, these tumors can restore their homologous recombination capabilities during treatment, leading to rapid disease recurrence and platinum resistance. Developing assays that can reliably monitor BRCA methylation status over time remains an active area of translational research.

Harnessing the Immune Response

The intersection of DNA damage repair defects and tumor immunogenicity is another promising frontier. HR-deficient tumors, particularly those with BRCA mutations, typically exhibit a higher burden of neoantigens, leading to increased infiltration of tumor-infiltrating lymphocytes (TILs) and elevated expression of PD-1 and PD-L1.

While early trials of immune checkpoint inhibitors in unselected ovarian cancer patients yielded disappointing results, emerging subset analyses suggest that combining checkpoint inhibitors with PARP inhibitors may produce synergistic effects in patients with specific DNA repair deficiencies.

Clinically Addressing BRCA Reversion Mutations

Perhaps the most striking mechanism of PARP inhibitor resistance is the occurrence of BRCA reversion mutations. In these cases, a tumor harboring a non-functional, mutated BRCA1 or BRCA2 gene acquires secondary mutations that restore the gene’s open reading frame, bringing back functional homologous recombination repair.

When this happens, the historic "genomic scars" remain visible in the DNA, but the tumor is no longer functionally HRD. This phenomenon highlights the limitations of static genomic scar assays and underscores the need for functional, real-time biomarkers of homologous recombination activity.

As molecular diagnostics continue to advance, the field is moving away from basic binary classifications. By integrating genomic scar scores, comprehensive mutation panels, cell cycle regulators like RB1 and CCNE1, and immune-microenvironment profiling, pathologists will be better equipped to guide highly personalized, effective treatment strategies for patients with ovarian cancer.